Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Knoebl

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Haematologica|May 9, 2020
International recommendations on the diagnosis and treatment of acquired hemophilia AAndreas Tiede, Peter Collins, Paul Knoebl, et al.
Hamostaseologie|December 4, 2023
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working GroupChristian Pfrepper, Robert Klamroth, Johannes Oldenburg, et al.
Blood Advances|April 21, 2021
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysisFlora Peyvandi, Spero Cataland, Marie Scully, et al.
Journal of Thrombosis and Haemostasis : JTH|November 7, 2019
Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES studyPaul Knoebl, Spero Cataland, Flora Peyvandi, et al.
Research and Practice in Thrombosis and Haemostasis|August 5, 2024
Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 studyHuyen Tran, Sylvia von Mackensen, Aby Abraham, et al.
Annals of Hematology|July 7, 2014
Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unitPhilipp Wohlfarth, Thomas Staudinger, Wolfgang R Sperr, et al.
Journal of Thrombosis and Haemostasis : JTH|June 27, 2024
Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia AChristina Hart, Robert Klamroth, Ulrich J Sachs, et al.
American Journal of Hematology|January 2, 2023
N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemiaIrene Graf, Georg Greiner, Rodrig Marculescu, et al.
American Journal of Hematology|July 13, 2017
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 yearsWolfgang R Sperr, Susanne Herndlhofer, Karoline Gleixner, et al.
Critical Care (London, England)|January 22, 2014
Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failurePhilipp Wohlfarth, Roman Ullrich, Thomas Staudinger, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Haematologica|May 9, 2020
International recommendations on the diagnosis and treatment of acquired hemophilia AAndreas Tiede, Peter Collins, Paul Knoebl, et al.
Hamostaseologie|December 4, 2023
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working GroupChristian Pfrepper, Robert Klamroth, Johannes Oldenburg, et al.
Blood Advances|April 21, 2021
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysisFlora Peyvandi, Spero Cataland, Marie Scully, et al.
Journal of Thrombosis and Haemostasis : JTH|November 7, 2019
Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES studyPaul Knoebl, Spero Cataland, Flora Peyvandi, et al.
Research and Practice in Thrombosis and Haemostasis|August 5, 2024
Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 studyHuyen Tran, Sylvia von Mackensen, Aby Abraham, et al.
Annals of Hematology|July 7, 2014
Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unitPhilipp Wohlfarth, Thomas Staudinger, Wolfgang R Sperr, et al.
Journal of Thrombosis and Haemostasis : JTH|June 27, 2024
Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia AChristina Hart, Robert Klamroth, Ulrich J Sachs, et al.
American Journal of Hematology|January 2, 2023
N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemiaIrene Graf, Georg Greiner, Rodrig Marculescu, et al.
American Journal of Hematology|July 13, 2017
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 yearsWolfgang R Sperr, Susanne Herndlhofer, Karoline Gleixner, et al.
Critical Care (London, England)|January 22, 2014
Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failurePhilipp Wohlfarth, Roman Ullrich, Thomas Staudinger, et al.
Pageof 4